Sage Journals: Discover world-class research

Abstract

Rivastigmine has beneficial effects on cognitive functioning in Alzheimer’s disease (AD). Effects of cholinesterase inhibitors, particularly rivastigmine, on AD Assessment Scale—cognitive subscale (ADAS-cog) domains and individual items have rarely been analyzed. Results from 4 randomized, double-blind, placebo-controlled, 26-week rivastigmine capsule trials in patients with mild-to-moderate AD were pooled and ADAS-cog domains and individual items were evaluated. Data were available from 878, 1053, and 863 patients in the 1 to 4 mg/d, 6 to 12 mg/d, and placebo groups, respectively. Rivastigmine-treated groups were superior to placebo on total ADAS-cog and memory domain scores (P ≤ .0001). Rivastigmine 6 to 12 mg/d was also significantly better versus placebo on language (P < .001) and praxis (P < .001); greatest treatment responses were seen on memory items (P < .0001). Although rivastigmine was associated with dose-dependent improvements in all cognitive domains, largest effects were on memory items. Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment.

Keywords

Alzheimer’s disease cognition language memory praxis rivastigmine

References

Davies P. , Maloney AJ Selective loss of central cholinergic neurons in Alzheimer’s disease . Lancet. 1976;2(8000):1403.

Rosenstein LD Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev. 1998 ;8(3):109-167.

Cummings JL Alzheimer’s disease. N Engl J Med. 2004 ; 351(1):56-67.

Rosen WG , Mohs RC , Davis KL A new rating scale for Alzheimer’s disease. Am J Psychiatry . 1984;141(11):1356-1364.

Winblad B. , Brodaty H. , Gauthier S. , et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16(7):653-666.

Benge JF , Balsis S. , Geraci L. , Massman PJ , Doody RS

How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer’s disease?

Dement Geriatr Cogn Disord. 2009;28(1):63-69.

Rösler M. , Anand R. , Cicin-Sain A. , et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318(7184): 633-638.

Feldman HH , Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry . 2007;78(10):1056-1063.

Schneider LS , Anand R. , Farlow MR Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1(suppl 1):S26-S34.

10.

Corey-Bloom J. , Anand R. , Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease . Int J Geriatr Psychopharmacol. 1998;1(2):55-65.

11.

Birks J. , Grimley Evans J. , Iakovidou V. , Tsolaki M. , Holt FE Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2009;(2):CD001191.

12.

Reitz C. , Honig L. , Vonsattel JP , Tang MX , Mayeux R. Memory performance is related to amyloid and tau pathology in the hippocampus . J Neurol Neurosurg Psychiatry. 2009;80(7):715-721.

13.

Mohs RC , Knopman D. , Petersen RC , et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2): S13-S21.

14.

Olin J. , Schneider L. Assessing response to tacrine using the factor analytic structure of the Alzheimer’s Disease Assessment Scale (ADAS) cognitive subscale. Int J Geriatr Psychiatry. 1995;10(9):753-756.

15.

Venneri A. , Shanks MF , Staff RT , et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease. Neuroreport. 2002;13(1):83-87.

16.

Adler G. , Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001;43(4):273-276.

17.

Nordberg A. , Darreh-Shori T. , Svensson A. , Guan Z. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci. 2001;187(suppl 1):P0144.

18.

Bullock R. , Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res. 2007;4(3): 277-293.

19.

Raskind MA , Peskind ER , Wessel T. , Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology . 2000;54(12):2261-2268.

20.

Rogers SL , Farlow MR , Doody RS , Mohs R. , Friedhoff LT A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology . 1998;50(1):136-45.

21.

Rockwood K. , Mintzer J. , Truyen L. , Wessel T. , Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001;71(5):589-595.

Effects of Oral Rivastigmine on Cognitive Domains in Mild-to-Moderate Alzheimer’s Disease

Abstract

Keywords

References